Neurology & Immunology
Multiple sclerosis (MS) is a chronic condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide.1
For more than 20 years, we have been relentlessly focused on understanding the challenges people living with MS face to improve the healthcare experience for them and the broader MS Community.
Addressing the Challenge
MS in the 21st Century
MS in the 21st Century is our company-sponsored initiative, where MS experts and MS patients work together to find ways to improve communication between healthcare professionals and people living with MS.
MS in the 21st Century is an entirely collaborative group, with the primary objectives being to improve communication between healthcare professionals and people with MS, and to work together to develop practical educational resources based on real-world needs and data.
Supporting World MS Day
Every year on May 30th, the global MS community comes together to mark World Multiple Sclerosis Day. Led by the Multiple Sclerosis International Federation (MSIF), national MS societies, researchers, nurses, rehabilitation experts and doctors, as well as people living with MS and their families unite to share stories, raise awareness, and campaign for greater support for the MS community.
We support these efforts by amplifying the MSIF campaign and raising awareness to spotlight the unseen impact of MS around the world.
“World MS Day is all about connecting people affected by MS, raising awareness, and global solidarity. Around 2.8 million people live with MS around the world, and many have little access to support. The MS Connections campaign is all about building community connection, self-connection and connections to quality care. We are very happy that Merck KGaA, Darmstadt, Germany is supporting World MS Day 2021 to help make sure that people affected by MS have their voices heard."
– Peer Baneke, CEO, MS International Federation
Patient-focused drug development in MS
As part of EMD Serono’s commitment to patient-focused drug development, we collaborated with the Accelerated Cure Project for Multiple Sclerosis (ACP), a patient-founded non-profit organization dedicated to accelerating research efforts to improve diagnoses, optimizing treatment outcomes, and developing cures for MS.
Enabled by our collaboration with ACP, we tapped into a research initiative called iConquerMS™, which enables individuals living with MS to contribute their perspectives, ideas, and data to researchers, to integrate patient perspectives into the design and implementation of two ongoing clinical trials.
Through this innovative collaboration, individuals living with MS provided feedback on the choice of patient-reported outcome (PRO) endpoints in the trials and insights on patient-facing materials.
1 MS International Federation. Atlas of MS Third Edition. Available at: https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. Accessed July 2021.